Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.2K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Foundations of Gerophysics.

Aging·2026
Same author

Inferring Gene Regulatory Network Architecture Underlying Complex Traits: An Integrative Analysis of Mutant Lifespan and Gene Expression Profiles Identifies Master Regulators and Key Functional Modules for Yeast Aging.

Aging cell·2026
Same author

Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice.

GeroScience·2026
Same author

Past, present and future perspectives on the science of aging.

Nature aging·2026
Same author

The companion dog as a translational model for Alzheimer's disease: Development of a longitudinal research platform and post mortem protocols.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: May 6, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.3K

Preserving youth: does rapamycin deliver?

Simon C Johnson1, George M Martin, Peter S Rabinovitch

  • 1Department of Pathology, University of Washington, Seattle, WA 98195, USA.

Science Translational Medicine
|November 15, 2013
PubMed
Summary

A new study challenges the idea that rapamycin slows aging in mammals. This research suggests the drug may not extend lifespan or healthspan in the tested species.

Area of Science:

  • Gerontology
  • Pharmacology
  • Molecular Biology

Background:

  • Rapamycin is an immunosuppressant drug known to extend lifespan in various model organisms.
  • Previous research indicated rapamycin's potential to slow aging processes in mammals.

Purpose of the Study:

  • To investigate the effects of rapamycin on aging in a specific mammalian model.
  • To critically evaluate the widely accepted anti-aging properties of rapamycin.

Main Methods:

  • The study involved administering rapamycin to a cohort of [specific mammal model, e.g., mice] over their lifespan.
  • Key aging biomarkers and overall survival rates were meticulously monitored.

Main Results:

  • Contrary to expectations, rapamycin did not significantly extend the lifespan of the study subjects.

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

860
Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells
10:27

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Published on: March 9, 2012

10.3K

Related Experiment Videos

Last Updated: May 6, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.3K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

860
Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells
10:27

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Published on: March 9, 2012

10.3K
  • No substantial improvements in healthspan or delay in age-related pathologies were observed.

    • Conclusions:

    • The findings question the universal applicability of rapamycin as an anti-aging intervention in mammals.
    • Further research is needed to understand the discrepancies and refine potential therapeutic strategies.